DaVita Launches Landmark Studies on Middle-Molecule Clearance in Kidney Failure Patients

Reuters
2025/10/20
DaVita Launches Landmark Studies on Middle-Molecule Clearance in Kidney Failure Patients

DaVita Inc. has announced the launch of two new initiatives, MODEL and MEMOIRS, aimed at enhancing the understanding of middle-molecule removal in dialysis treatments for patients with end stage kidney disease (ESKD). These initiatives will collectively involve approximately 9,000 adults over the next two years. The MODEL initiative is a quality improvement project evaluating the survival of U.S. patients treated with medium cut-off dialyzers, while the MEMOIRS survey is a prospective cohort study comparing patient-reported outcomes between treatments using medium cut-off and high-flux dialyzers. The studies seek to generate first-of-its-kind U.S. data on the clinical outcomes and quality of life impacts of middle-molecule clearance. The results of these initiatives have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DaVita Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA01427) on October 20, 2025, and is solely responsible for the information contained therein.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10